公开(公告)号：US20240158851A1

公开(公告)日：2024-05-16

申请号：US18420013

申请日：2024-01-23

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In IM ,  Baek Sun KIM ,  Sung Hyun TAG

IPC: C12Q1/6876

CPC classification number: C12Q1/6876 ,  C12Q1/686 ,  C12Q2600/178

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

公开(公告)号：US20230075981A1

公开(公告)日：2023-03-09

申请号：US17745416

申请日：2022-05-16

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In IM ,  Sangjoon LEE ,  Ji Eun CHOI

IPC: C12N15/113 ,  A61P25/28

Abstract: Disclosed is a composition for preventing or treating a degenerative brain disease. The composition includes, as an active ingredient, a MECP2 inhibitor for treating the degenerative brain disease, a polynucleotide encoding the MECP2 inhibitor or a recombinant virus containing the MECP2 inhibitor. The composition is useful for the treatment of a degenerative brain disease (particularly Alzheimer's syndrome) caused by beta-amyloid. In addition, the composition is effective in improving or ameliorating deterioration of cognitive functions and social deficits caused by Alzheimer's syndrome.

公开(公告)号：US20210403996A1

公开(公告)日：2021-12-30

申请号：US17334345

申请日：2021-05-28

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In IM ,  Byung Sun KIM ,  Sung Hyun TAG

IPC: C12Q1/6876

Abstract: Disclosed is a composition for diagnosing, preventing or treating drug addiction based on synaptotagmin binding cytoplasmic RNA interacting protein (SYNCRIP). SYNCRIP or a gene encoding the protein can be used to diagnose drug addiction. In addition, a therapeutic agent for drug addiction can be discovered by measuring the expression of SYNCRIP. Furthermore, an agent expressing SYNCRIP or promoting the activity of SYNCRIP can be used to prevent or treat drug addiction.

公开(公告)号：US20240358853A1

公开(公告)日：2024-10-31

申请号：US18598746

申请日：2024-03-07

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Heh-In IM ,  Jin Hee BAE ,  Nazarii FRANKIV

IPC: A61K48/00 ,  A61K9/00 ,  A61K38/17 ,  A61P25/24 ,  C12N15/86 ,  G01N33/68

CPC classification number: A61K48/005 ,  A61K9/0019 ,  A61K38/1709 ,  A61P25/24 ,  C12N15/86 ,  G01N33/6854 ,  G01N33/6893 ,  C12N2750/14143

Abstract: According to the present disclosure, the relation between the MeCP2 expression level and depression in D2R neurons of the ventral striatum was first found, and it was confirmed that MeCP2 in D2R neurons of the ventral striatum was significantly decreased due to depressive symptoms, and depressive symptoms were improved when MeCP2 expression in the neurons was up-regulated. Accordingly, the expression level of MeCP2 in D2R neurons of the ventral striatum is provided as a biomarker for diagnosing depression and the up-regulation of the MeCP2 expression is provided as a treatment strategy for depression, and thus, it is expected to be useful as a development platform for drugs for preventing or treating depression in the future.